SmithKline Beecham LYMErix Posts $18 Mil. In First Quarter Sales
SmithKline Beecham's Lyme disease vaccine is off to a "solid" start in the U.S., the company said.
You may also be interested in...
GlaxoSmithKline has ceased production of Lymerix and will not be selling its remaining inventory of the Lyme disease vaccine
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011